Stoke Therapeutics, Inc. Operating Leases, Rent Expense
Stoke Therapeutics, Inc. (STOK) reported Operating Leases, Rent Expense of $1.10 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-23.
Discontinued
us-gaap:LeaseAndRentalExpense · last filed 2020-03-23
- Stoke Therapeutics, Inc. operating leases, rent expense for the quarter ending 2019-12-31 was $300.00K, a 200.00% increase year-over-year.
- Stoke Therapeutics, Inc. operating leases, rent expense for the quarter ending 2019-09-30 was $300.00K, a 200.00% increase year-over-year.
- Stoke Therapeutics, Inc. operating leases, rent expense for the quarter ending 2019-06-30 was $260.00K, a 271.43% increase year-over-year.
- Stoke Therapeutics, Inc. operating leases, rent expense for the quarter ending 2019-03-31 was $240.00K.
- Stoke Therapeutics, Inc. operating leases, rent expense for fiscal 2019 was $1.10M, a 266.67% increase from fiscal 2018.
- Stoke Therapeutics, Inc. operating leases, rent expense for fiscal 2018 was $300.00K.
| Period end | Operating Leases, Rent Expense 3 month | Operating Leases, Rent Expense 6 month | Operating Leases, Rent Expense 9 month | Operating Leases, Rent Expense 12 month |
|---|---|---|---|---|
| 2019-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-23 | $600.00K derived: sum of 2 quarters · filed 2020-03-23 | $860.00K derived: sum of 3 quarters · filed 2020-03-23 | $1.10M 10-K · filed 2020-03-23 |
| 2019-09-30 | $300.00K 10-Q · filed 2019-11-12 | $560.00K derived: sum of 2 quarters · filed 2019-11-12 | $800.00K 10-Q · filed 2019-11-12 | $900.00K derived: sum of 4 quarters · filed 2020-03-23 |
| 2019-06-30 | $260.00K 10-Q · filed 2019-08-14 | $500.00K 10-Q · filed 2019-08-14 | $600.00K derived: sum of 3 quarters · filed 2020-03-23 | $700.00K derived: sum of 4 quarters · filed 2020-03-23 |
| 2019-03-31 | $240.00K derived: 10-K 12 month − 3 quarters · filed 2020-03-23 | $340.00K derived: sum of 2 quarters · filed 2020-03-23 | $440.00K derived: sum of 3 quarters · filed 2020-03-23 | $510.00K derived: sum of 4 quarters · filed 2020-03-23 |
| 2018-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-23 | $200.00K derived: sum of 2 quarters · filed 2020-03-23 | $270.00K derived: sum of 3 quarters · filed 2020-03-23 | $300.00K 10-K · filed 2020-03-23 |
| 2018-09-30 | $100.00K 10-Q · filed 2019-11-12 | $170.00K derived: sum of 2 quarters · filed 2019-11-12 | $200.00K 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $70.00K 10-Q · filed 2019-08-14 | $100.00K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |